HC Wainwright restated their buy rating on shares of Ocular Therapeutix (NASDAQ:OCUL – Free Report) in a research note published on Tuesday, Benzinga reports. The brokerage currently has a $12.00 price objective on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Ocular Therapeutix’s Q3 2023 earnings at ($0.28) EPS, Q4 2023 earnings at […]
HC Wainwright reissued their buy rating on shares of Ocular Therapeutix (NASDAQ:OCUL – Free Report) in a report released on Tuesday, Benzinga reports. HC Wainwright currently has a $12.00 price target on the biopharmaceutical company’s stock. OCUL has been the subject of several other research reports. Robert W. Baird boosted their price objective on shares […]
Ocular Therapeutix (NASDAQ:OCUL – Free Report) and Innoviva (NASDAQ:INVA – Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations. Risk & Volatility Ocular Therapeutix has a beta of 1.22, […]
Several analysts have recently updated their ratings and price targets for Ocular Therapeutix (NASDAQ: OCUL): 6/22/2023 – Ocular Therapeutix was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating. 6/14/2023 – Ocular Therapeutix was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating. 6/13/2023 – Ocular Therapeutix […]
StockNews.com downgraded shares of Ocular Therapeutix (NASDAQ:OCUL – Get Rating) from a hold rating to a sell rating in a research note issued to investors on Thursday morning. Other equities analysts have also recently issued research reports about the stock. JMP Securities boosted their price objective on shares of Ocular Therapeutix from $11.00 to $12.00 […]